O T C
PAOG Cannabis Pharmaceutical and Nutraceutical 2021 Strategy Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2021

  Sandusky, OH – January 11, 2021 – PAO Group, Inc. (OTC PINK: PAOG) today announced an update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts, Inc. (OTC

PAOG Develops CBD Nutraceutical For $12.7 Billion Market From Patented Extract Process

  Sandusky, OH, December 18, 2020 – OTC PR WIRE – PAO Group, Inc. (OTC US: PAOG) today announced the company expects to generate its first revenue next year in 2021 from its Cannabidiol (CBD) extraction technology, RespRx, acquired in July of this year, 2020. Yesterday, PAOG announced an engagement with the Puerto Rico Consortium

PAOG Announces Puerto Rico Consortium For Clinical Investigation Engagement To Advance CBD COPD Nutraceutical Care Solution

  Sandusky, OH, December 17, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC US: PAOG) today announced an engagement with the Puerto Rico Consortium for Clinical Investigation to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary

PAOG CEO Discusses 2020 Progress And PURA Dividend On MoneyTV

Sandusky, OH – November 25, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC: PAOG) today announced an interview of CEO Jim DiPrima on MoneyTV where Mr. DiPrima discusses the company’s progress in 2020 to include the latest updates on PAOG’s coming one for one dividend of PAOG stock to Puration, Inc. (OTC: PURA)

PAOG Publishes First Financial Report Following Two Strategic Acquisitions

Dallas, Texas, November 17, 2020 – OTC PR WIRE – PAO Group, Inc. (OTC US: PAOG) today announced publishing its Q3 2020 report with OTC Markets. This is the first report since making two strategic acquisitions in the course of the third quarter. PAOG transitioned its business direction in the previous quarter making the acquisition

PURA CEO Interviewed About His Plan For $26 Billion Hemp Market By CEO Roadshow

Dallas, Texas, November 16, 2020 – Puration, Inc. (OTC US: PURA) today announced the release of an interview of CEO Brian Shibley conducted by CEO Roadshow in association with OTC PR Wire (www.otcprwire.com) – the #1 solution for press, financial disclosure and multimedia solutions for companies trading in the OTC Market. In the interview, Mr.

PAOG Signs Clinical Research Organization (CRO) To Advance Respiratory Cannabis Treatment Through Regulatory Approval

Sandusky, OH – October 23, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG signed the agreement yesterday,

PURA Corporate Update To Include Latest On PAOG Dividend Scheduled For Tomorrow

Dallas, TX – October 22, 2020 – OTC PR WIRE — Puration, Inc. (OTC PINK: PURA) today confirmed a comprehensive corporate update scheduled for tomorrow, Friday, October 23, 2020, to provide the latest information on progress with the new Farmersville Brand strategy.  The update was coordinated to follow yesterday’s announcement of the contract to acquire

PAOG Advances FDA Application Process For Respiratory Cannabis Drug Treatment

Sandusky, OH – October 20, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced the company plans to release a new key update this Friday, October 23, 2020, on its progress to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG announced last week

PAOG Releases Cannabis Drug Development Update

Sandusky, OH – October 15, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today published a progress update on the company’s ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG anticipates entering into an agreement with a contract research organization (CRO) within

Recent Posts

Recent Posts

Contact Us

All Rights Reserved © 2019